MA47522A - Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation - Google Patents

Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Info

Publication number
MA47522A
MA47522A MA047522A MA47522A MA47522A MA 47522 A MA47522 A MA 47522A MA 047522 A MA047522 A MA 047522A MA 47522 A MA47522 A MA 47522A MA 47522 A MA47522 A MA 47522A
Authority
MA
Morocco
Prior art keywords
vectors
compositions
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA047522A
Other languages
English (en)
Other versions
MA47522B1 (fr
Inventor
Benoit C S Callendret
Anders Krarup
Johannes Petrus Maria Langedijk
Jörn Stitz
Manen Danielle Van
Jort Vellinga
Frank Wegmann
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA47522A publication Critical patent/MA47522A/fr
Publication of MA47522B1 publication Critical patent/MA47522B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA47522A 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation MA47522B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17

Publications (2)

Publication Number Publication Date
MA47522A true MA47522A (fr) 2021-05-05
MA47522B1 MA47522B1 (fr) 2021-11-30

Family

ID=57737697

Family Applications (3)

Application Number Title Priority Date Filing Date
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Country Status (30)

Country Link
US (3) US10369214B2 (fr)
EP (3) EP3964569A1 (fr)
JP (2) JP6510149B2 (fr)
KR (1) KR20180086207A (fr)
CN (2) CN108368157B (fr)
AU (2) AU2016369326B2 (fr)
BR (1) BR112018011122A2 (fr)
CA (1) CA3008542C (fr)
CY (2) CY1122705T1 (fr)
DK (2) DK3584252T3 (fr)
EA (1) EA038974B1 (fr)
ES (2) ES2753854T3 (fr)
HR (2) HRP20191902T1 (fr)
HU (2) HUE045993T2 (fr)
IL (1) IL259942B2 (fr)
LT (2) LT3390430T (fr)
MA (3) MA47522B1 (fr)
MD (2) MD3584252T2 (fr)
ME (1) ME03545B (fr)
MX (2) MX383507B (fr)
PH (1) PH12018501047A1 (fr)
PL (2) PL3584252T3 (fr)
PT (1) PT3390430T (fr)
RS (2) RS62360B1 (fr)
SG (2) SG10202109457RA (fr)
SI (2) SI3584252T1 (fr)
SM (2) SMT201900629T1 (fr)
TW (2) TWI707039B (fr)
WO (1) WO2017102929A1 (fr)
ZA (1) ZA201803978B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
MX392862B (es) 2016-06-16 2025-03-24 Janssen Vaccines & Prevention Bv Formulación de vacuna contra el vih.
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
WO2018229711A1 (fr) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
CA3069052A1 (fr) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere
WO2019055888A1 (fr) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Méthodes pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
UY37975A (es) * 2017-11-17 2019-02-28 Grifols Diagnostic Solutions Inc Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos
US20220211835A1 (en) * 2019-04-17 2022-07-07 The Wistar Institute Replication Deficient Adenoviral Vectors for HIV Vaccine Applications
WO2020237052A1 (fr) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets suivant un traitement antirétroviral
CN114585639A (zh) 2019-11-07 2022-06-03 扬森疫苗与预防公司 蛋白质纯化
WO2021228816A1 (fr) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration de vecteurs adénoviraux homologues
WO2021249011A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin contre le vih, procédés et utilisations associées
WO2022006095A2 (fr) * 2020-06-29 2022-01-06 Duke University Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc
WO2022084333A1 (fr) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Régimes de vaccin contre le vih
WO2022180007A1 (fr) 2021-02-23 2022-09-01 Janssen Vaccines & Prevention B.V. Mutation de protéine d'enveloppe du vih stabilisant un trimère
WO2022272275A1 (fr) * 2021-06-25 2022-12-29 Janssen Vaccines & Prevention B.V. Combinaisons de vaccins et d'anticorps neutralisants pour le traitement d'une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
WO2023242155A1 (fr) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions et procédés pour le diagnostic d'une infection par le vih

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (fr) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Trimeres stabilises solubles de glycoproteines
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
CA2785699A1 (fr) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
WO2003004657A1 (fr) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
WO2004044155A2 (fr) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center Mip-1$g(a) et gm-csf adjuvants de la reponse immune
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
EP2363143A3 (fr) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA exprimant des gènes enveloppe, gag et pol du vih
EP1667631A4 (fr) 2003-09-15 2010-04-14 Novartis Vaccines & Diagnostic Approches combinees pour produire des reponses immunitaires
WO2005052119A2 (fr) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants de la reponse immunitaire
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
AU2005243730B2 (en) * 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
EP1766097A4 (fr) 2004-06-15 2008-03-19 Progenics Pharm Inc Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
EP1784416B1 (fr) 2004-07-16 2011-10-05 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccins contre le sida comprenant des constructions d'acides nucleiques cmv/r
EP2319860A3 (fr) * 2004-08-27 2011-06-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus MVA de recombinaison exprimant les gènes modifiés env, gag et pol du VIH variantes A/G, B, et C
KR101253363B1 (ko) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
CA2656741A1 (fr) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur
CA2620874A1 (fr) 2005-08-23 2007-03-01 The Regents Of The University Of California Vaccin polyvalent
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
CA2655934A1 (fr) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Proteines env vih trimeriques solubles stabilisees et leurs utilisations
CA2667358A1 (fr) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifies en provenance d'isolats du vih-1, compositions, complexes trimeriques et utilisations de ceux-ci
WO2008140579A2 (fr) 2006-11-17 2008-11-20 New York University Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
EP4549461A3 (fr) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Anticorps neutralisant le virus de l'immunodéficience humaine (vih)
WO2012082918A1 (fr) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins contre filovirus d'adénovirus de sérotype 26 et sérotype 35
AP2013007180A0 (en) * 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
WO2013036791A2 (fr) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Vecteurs adénoviraux modifiés et procédés de traitement dans lesquels ils interviennent
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
WO2013040766A1 (fr) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih
EP2766037A4 (fr) 2011-10-12 2015-08-05 Scripps Research Inst Mini boucle v3 de gp120 du vih-1 et ses utilisations
WO2014047261A1 (fr) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Virus associés à l'immunodéficience et l'entéropathie et procédés d'utilisation de ceux-ci
WO2014078688A2 (fr) 2012-11-16 2014-05-22 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinants et leur utilisation
SG10201705880QA (en) 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10716845B2 (en) * 2013-10-04 2020-07-21 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
JP2017507672A (ja) * 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
DK3271729T3 (da) * 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
MX392862B (es) 2016-06-16 2025-03-24 Janssen Vaccines & Prevention Bv Formulación de vacuna contra el vih.
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
IL259942B2 (en) 2023-04-01
HUE055916T2 (hu) 2021-12-28
MA44059B1 (fr) 2019-11-29
HUE045993T2 (hu) 2020-01-28
SMT202100623T1 (it) 2022-01-10
IL259942A (en) 2018-07-31
SI3390430T1 (sl) 2019-12-31
US20170165355A1 (en) 2017-06-15
TWI792091B (zh) 2023-02-11
MA47522B1 (fr) 2021-11-30
US20210220468A1 (en) 2021-07-22
CN114686495A (zh) 2022-07-01
KR20180086207A (ko) 2018-07-30
MD3584252T2 (ro) 2022-01-31
CA3008542A1 (fr) 2017-06-22
MA44059A (fr) 2018-10-24
IL259942B (en) 2022-12-01
AU2016369326B2 (en) 2019-02-21
PH12018501047A1 (en) 2018-12-17
US11896663B2 (en) 2024-02-13
LT3390430T (lt) 2019-11-25
JP2019505188A (ja) 2019-02-28
SG11201804411TA (en) 2018-06-28
MA55825A (fr) 2022-03-09
TWI707039B (zh) 2020-10-11
TW201734210A (zh) 2017-10-01
US10369214B2 (en) 2019-08-06
MD3390430T2 (ro) 2019-12-31
RS62360B1 (sr) 2021-10-29
EA038974B1 (ru) 2021-11-17
CY1122705T1 (el) 2021-03-12
AU2019203468B2 (en) 2020-05-21
MX383507B (es) 2025-03-14
US20190321462A1 (en) 2019-10-24
LT3584252T (lt) 2021-09-27
CN108368157A (zh) 2018-08-03
AU2019203468A1 (en) 2019-06-06
MX2018007198A (es) 2018-08-01
EP3584252A1 (fr) 2019-12-25
EP3390430B1 (fr) 2019-08-28
EA201891415A8 (ru) 2019-10-31
US10973907B2 (en) 2021-04-13
AU2016369326A1 (en) 2018-06-07
JP6959289B2 (ja) 2021-11-02
CY1125387T1 (el) 2023-03-24
HRP20191902T1 (hr) 2020-01-24
PL3390430T3 (pl) 2020-03-31
JP2019146574A (ja) 2019-09-05
MX2021006931A (es) 2021-07-07
PT3390430T (pt) 2019-11-20
RS59447B1 (sr) 2019-11-29
CA3008542C (fr) 2020-06-02
SI3584252T1 (sl) 2021-11-30
ES2898271T3 (es) 2022-03-04
EP3964569A1 (fr) 2022-03-09
TW202106701A (zh) 2021-02-16
BR112018011122A2 (pt) 2018-11-21
ZA201803978B (en) 2021-05-26
DK3390430T3 (da) 2019-11-18
SG10202109457RA (en) 2021-10-28
ES2753854T3 (es) 2020-04-14
DK3584252T3 (da) 2021-11-15
JP6510149B2 (ja) 2019-05-08
EP3390430A1 (fr) 2018-10-24
EP3584252B1 (fr) 2021-08-25
EA201891415A1 (ru) 2018-11-30
ME03545B (fr) 2020-07-20
SMT201900629T1 (it) 2020-01-14
WO2017102929A1 (fr) 2017-06-22
PL3584252T3 (pl) 2022-01-10
CN108368157B (zh) 2022-04-15
HRP20211566T1 (hr) 2022-03-04

Similar Documents

Publication Publication Date Title
MA47522A (fr) Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
EP3717636A4 (fr) Variants de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
EP3341017A4 (fr) Compositions d'immunomodulation et leurs procédés d'utilisation
EP3390676A4 (fr) Adjuvants de lixiviation et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3364986A4 (fr) Compositions de plasma et leurs procédés d'utilisation
EP3303436A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation
EP3368547A4 (fr) Virus rsv chimère, compositions immunogènes et procédés d'utilisation
MA45982A (fr) Compositions de neurostéroïdes et leurs procédés d'utilisation
MA46586A (fr) Compositions de terlipressine et leurs procédés d'utilisation